A common misconception among buyers new to medical device sourcing is that "medical-grade silicone" is simply a raw material certification - a compound that comes with the right paperwork, molded the same way any other liquid silicone rubber part would be. In practice, achieving genuine ISO 10993 biocompatibility compliance for a finished part depends heavily on how the part is molded, not only on which raw material grade was used to start.
What ISO 10993 Actually Evaluates
ISO 10993 is a series of standards covering the biological evaluation of medical devices, assessing risks such as cytotoxicity, sensitization, irritation, and - depending on the intended use and contact duration - a range of additional biological endpoints. Critically, these evaluations are typically performed on the finished part, not just the raw material, because the biological risk profile depends on what actually leaches or extracts from the part as manufactured - not on the theoretical purity of the resin before it was processed.
This distinction matters because it means the molding process itself becomes part of what determines whether a device passes biocompatibility testing.
Where the Molding Process Diverges From Standard Industrial Practice
1. Cure Completeness and Residuals
Industrial-grade LSR parts can sometimes tolerate a degree of undercure or residual volatile content without causing a functional or commercial problem. For medical-grade parts, incomplete cure or elevated levels of extractable residuals directly threatens biocompatibility results, because uncured or partially reacted material is more likely to leach compounds during extraction testing. This generally requires:
More conservative, well-validated cure profiles rather than the fastest cycle time that still produces an acceptable-looking part
Consistent use of a secondary post-cure bake to drive off residual volatiles, which is sometimes treated as optional in industrial production but is standard practice for medical components
2. Mold Release Agents and Surface Treatments
Many conventional mold release agents are unsuitable for medical-grade production, because residues on the part surface can themselves introduce extractable substances or interfere with biocompatibility testing. Medical-grade molding generally requires either:
Release agents specifically validated as biocompatible and low-residue, or
Mold surface treatments and part geometry designed to minimize or eliminate the need for release agents altogether
3. Cleanroom or Controlled Environment Requirements
While not every medical silicone part requires a full cleanroom, many require a controlled environment well beyond typical industrial molding conditions - controlling particulate contamination, airborne contaminants, and cross-contamination risk from other materials or chemistries processed in the same facility. This affects not just the molding cell itself but material handling, storage, and packaging processes upstream and downstream of molding.
4. Cross-Contamination Control From Other Chemistries
As with cure-inhibition risk more broadly, medical-grade production requires stricter control over shared equipment, tooling, and handling processes to avoid trace contamination from non-medical-grade materials, other silicone chemistries, or general industrial contaminants that wouldn't be flagged as a problem in standard industrial production but can affect biocompatibility test outcomes.
5. Traceability and Documentation
ISO 10993 compliance for a finished device typically depends on a documented, traceable process - raw material lot tracking, process parameter records, and validated, repeatable process conditions - rather than the more informal quality control that can be sufficient for many industrial applications. A change to mold temperature, cure time, or even release agent lot that wouldn't be documented in an industrial setting needs to be tracked and controlled in a medical-grade process, because any of these changes can affect biocompatibility results.
Why This Matters for Buyers Evaluating a Manufacturing Partner
A supplier capable of molding excellent industrial-grade LSR parts is not automatically equipped to produce parts that will pass biocompatibility testing, even using the same base raw material grade. The relevant questions for supplier qualification go well beyond raw material certificates:
Does the facility have a documented, validated process specifically for medical-grade parts, including defined post-cure procedures?
What mold release agents are used for medical-grade tooling, and have they been validated as compatible with biocompatibility testing?
Is medical-grade production physically or procedurally separated from other silicone chemistries and industrial-grade production to control cross-contamination risk?
What level of process documentation and traceability is maintained, and can it support a design history file or biocompatibility testing submission?
The Practical Takeaway
Choosing a "medical-grade" raw material is a necessary starting point, but it doesn't by itself guarantee a finished part will pass ISO 10993 evaluation. The molding process - cure profile, release agent selection, contamination control, and documentation - is where biocompatibility compliance is actually built or lost. For buyers sourcing medical silicone components, supplier qualification should evaluate the full process, not just the material data sheet.












